Dianax SpA has obtained a grant from the European Commission to support its R&D program

July 2016 — Dianax SpA has obtained a public grant from the European Commission in order to support its R&D program for the development of a revolutionary lab-on-chip technology.

Founded in 2013, Dianax is a start-up focusing on the development of lab-on-chip medical devices for diagnostics via protein biomarkers analysis in raw samples. The company's mission is the development and introduction in the market of lab-on-chip for protein detection in medical diagnostic, food industry and environmental controls. Dianax's technology (patented) ensures that flexible and robust chips can be incorporated in cartridges with standard interfaces such as USB or Firewire.

Our role in the transaction

Oaklins' team in Italy assisted Dianax along the entire process to access a public grant from the European Commission (EC). Given the high risk implicit in this R&D project, the ideal's source of funding was public. The team selected the right grant to apply to, assisted Dianax in the preparation of all the documentation needed for the application and submitted it to the EC. After the grant was approved, he team also negotiated the payment installments during the implementation of the R&D project, up to the final subscription of the Official Grant Agreement between Dianax and the EC.